title: Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
authors.forename: J
authors.initials: J
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Harigai
authors.forename: T
authors.initials: T
authors.lastname: Akashi
authors.forename: K
authors.initials: K
authors.lastname: Nagasaka
authors.forename: F
authors.initials: F
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Tominaga
authors.forename: N
authors.initials: N
authors.lastname: Miyasaka
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002908:Chronic Disease; D020031:Epstein-Barr Virus Infections / Q000139:chemically induced*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D019947:Receptors, Interleukin-6; C502936:tocilizumab